Literature DB >> 30426183

Comparison of local spectral modulation, and temporal correlation, of simultaneously recorded EEG/fMRI signals during ketamine and midazolam sedation.

Anna Forsyth1, Rebecca McMillan1, Doug Campbell2, Gemma Malpas2, Elizabeth Maxwell2, Jamie Sleigh3, Juergen Dukart4, Joerg F Hipp4, Suresh D Muthukumaraswamy5.   

Abstract

RATIONALE AND
OBJECTIVES: The identification of biomarkers of drug action can be supported by non-invasive brain imaging techniques, such as electroencephalography (EEG) and functional magnetic resonance imaging (fMRI), with simultaneous collection plausibly overcoming the limitations of either modality alone. Despite this, few studies have assessed the feasibility and utility of recording simultaneous EEG/fMRI in a drug study.
METHODS: We used simultaneous EEG/fMRI to assess the modulation of neural activity by ketamine and midazolam, in a placebo-controlled, single-blind, three-way cross-over design. Specifically, we analysed the sensitivity and direction of the spectral effects of each modality and the temporal correlations between the modulations of power of the common EEG bands and the blood-oxygen-level-dependent (BOLD) signal. RESULTS AND
CONCLUSIONS: Demonstrating feasibility, local spectral effects were similar to those found in previous non-simultaneous EEG and fMRI studies. Ketamine administration resulted in a widespread reduction of BOLD fractional amplitude of low frequency fluctuations (fALFF) and a diverse pattern of effects in the different EEG bands. Midazolam increased fALFF in occipital, parietal, and temporal areas, and frontal delta and beta EEG power. While EEG spectra were more sensitive to pharmacological modulations than the fALFF bands, there was no clear spatial relationship between the two modalities. Additionally, ketamine modulated the temporal correlation strengths between the theta EEG band and the BOLD signal, whereas midazolam altered temporal correlations with the alpha and beta bands. Taken together, these results demonstrate the utility of simultaneous recording: each modality provides unique insights, and combinatorial analyses elicit more information than separate recordings.

Entities:  

Keywords:  Electroencephalography; Frequency analysis; Functional magnetic resonance imaging; Ketamine; Midazolam; Simultaneous EEG/fMRI

Mesh:

Substances:

Year:  2018        PMID: 30426183     DOI: 10.1007/s00213-018-5064-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  78 in total

1.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

2.  Simultaneous EEG and fMRI of the alpha rhythm.

Authors:  Robin I Goldman; John M Stern; Jerome Engel; Mark S Cohen
Journal:  Neuroreport       Date:  2002-12-20       Impact factor: 1.837

3.  Alterations of the amplitude of low-frequency fluctuations in treatment-resistant and treatment-response depression: a resting-state fMRI study.

Authors:  Wen-bin Guo; Feng Liu; Zhi-min Xue; Xi-jia Xu; Ren-rong Wu; Chao-qiong Ma; Sarah C Wooderson; Chang-lian Tan; Xue-li Sun; Jin-dong Chen; Zhe-ning Liu; Chang-qing Xiao; Hua-fu Chen; Jing-ping Zhao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-28       Impact factor: 5.067

4.  Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo.

Authors:  David J Greenblatt; Eric Legangneux; Jerold S Harmatz; Estelle Weinling; Jon Freeman; Kathleen Rice; Gary K Zammit
Journal:  J Clin Pharmacol       Date:  2006-12       Impact factor: 3.126

5.  Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference.

Authors:  Stephen M Smith; Thomas E Nichols
Journal:  Neuroimage       Date:  2008-04-11       Impact factor: 6.556

6.  Finding thalamic BOLD correlates to posterior alpha EEG.

Authors:  Zhongming Liu; Jacco A de Zwart; Bing Yao; Peter van Gelderen; Li-Wei Kuo; Jeff H Duyn
Journal:  Neuroimage       Date:  2012-08-17       Impact factor: 6.556

Review 7.  The role of fMRI in drug development.

Authors:  Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins
Journal:  Drug Discov Today       Date:  2017-11-15       Impact factor: 7.851

Review 8.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

9.  Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.

Authors:  Joshua H Balsters; Redmond G O'Connell; Mary P Martin; Alessandra Galli; Sarah M Cassidy; Sophia M Kilcullen; Sonja Delmonte; Sabina Brennan; Jim F Meaney; Andrew J Fagan; Arun L W Bokde; Neil Upton; Robert Lai; Marc Laruelle; Brian Lawlor; Ian H Robertson
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Peak visual gamma frequency is modified across the healthy menstrual cycle.

Authors:  Rachael L Sumner; Rebecca L McMillan; Alexander D Shaw; Krish D Singh; Fred Sundram; Suresh D Muthukumaraswamy
Journal:  Hum Brain Mapp       Date:  2018-04-17       Impact factor: 5.038

View more
  8 in total

1.  Effects of Ketamine and Midazolam on Simultaneous EEG/fMRI Data During Working Memory Processes.

Authors:  Anna E M Forsyth; Rebecca McMillan; Juergen Dukart; Jörg F Hipp; Suresh D Muthukumaraswamy
Journal:  Brain Topogr       Date:  2021-10-13       Impact factor: 3.020

2.  Modulation of simultaneously collected hemodynamic and electrophysiological functional connectivity by ketamine and midazolam.

Authors:  Anna Forsyth; Rebecca McMillan; Doug Campbell; Gemma Malpas; Elizabeth Maxwell; Jamie Sleigh; Juergen Dukart; Jörg Hipp; Suresh D Muthukumaraswamy
Journal:  Hum Brain Mapp       Date:  2019-12-06       Impact factor: 5.038

3.  Comparative analysis of default mode networks in major psychiatric disorders using resting-state EEG.

Authors:  Kang-Min Choi; Jeong-Youn Kim; Yong-Wook Kim; Jung-Won Han; Chang-Hwan Im; Seung-Hwan Lee
Journal:  Sci Rep       Date:  2021-11-10       Impact factor: 4.379

4.  Alpha blocking and 1/fβ spectral scaling in resting EEG can be accounted for by a sum of damped alpha band oscillatory processes.

Authors:  Rick Evertz; Damien G Hicks; David T J Liley
Journal:  PLoS Comput Biol       Date:  2022-04-15       Impact factor: 4.779

5.  Electroencephalographic slow wave dynamics and loss of behavioural responsiveness induced by ketamine in human volunteers.

Authors:  Jamie Sleigh; Rebecca M Pullon; Phillip E Vlisides; Catherine E Warnaby
Journal:  Br J Anaesth       Date:  2019-09-03       Impact factor: 9.166

6.  Effects of ketamine and midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophrenia.

Authors:  Bhim M Adhikari; Juergen Dukart; Joerg F Hipp; Anna Forsyth; Rebecca McMillan; Suresh D Muthukumaraswamy; Meghann C Ryan; L Elliot Hong; Simon B Eickhoff; Neda Jahandshad; Paul M Thompson; Laura M Rowland; Peter Kochunov
Journal:  Hum Brain Mapp       Date:  2019-10-21       Impact factor: 5.038

Review 7.  Does mismatch negativity have utility for NMDA receptor drug development in depression?

Authors:  Nicholas Murphy; Marijn Lijffijt; Nithya Ramakrishnan; Bylinda Vo-Le; Brittany Vo-Le; Sidra Iqbal; Tabish Iqbal; Brittany O'Brien; Mark A Smith; Alan C Swann; Sanjay J Mathew
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

Review 8.  Case Studies Using the Electroencephalogram to Monitor Anesthesia-Induced Brain States in Children.

Authors:  Steven P Brandt; Elisa C Walsh; Laura Cornelissen; Johanna M Lee; Charles Berde; Erik S Shank; Patrick L Purdon
Journal:  Anesth Analg       Date:  2020-10       Impact factor: 6.627

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.